ArticleEuropean journal of medical research2025
UHRF1 silencing restrained the malignant phenotype of melanoma cells by inhibiting the HOXA9/HIF-1α axis-mediated glycolysis.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundUbiquitin-like with PHD and ring finger domains 1 (UHRF1) promotes DNA methylation of tumor suppressor genes, contributing to cancer development. Given its observed upregulation in melanoma, this study aimed to its functional roles and elucidate the underlying molecular mechanisms.
methodsUHRF1 protein levels was evaluated in human melanoma tissues and cell lines. Gain- and loss-of-function experiments were conducted in two melanoma cell lines (A357 and SK-MEL-28), and cell proliferation, invasion, and apoptosis were examined. Homeobox A9 (HOXA9) promoter methylation was assessed using methylation-specific PCR. HOXA9-mediated transcriptional regulation of hypoxia-inducible factor 1α (HIF-1α) was validated in melanoma cells. Glycolysis was evaluated by detecting glucose uptake, lactate production, ATP levels, and extracellular acidification rate (ECAR). Additionally, a xenograft model was established using UHRF1-knockdown A375 cells, and tumor growth was monitored in nude mice.
resultsUHRF1 was significantly upregulated in melanoma tissues and cell lines. UHRF1 overexpression facilitated melanoma cell proliferation and invasion and inhibited apoptosis, while UHRF1 silencing led to an opposite result. Mechanistically, UHRF1 promoted DNMT1-mediated HOXA9 promoter methylation and inhibited HOXA9 expression in melanoma cells. HOXA9 transcriptionally inhibited HIF-1α expression in melanoma cells. Consequently, UHRF1 overexpression upregulated HIF-1α expression in melanoma cells, thus promoting glycolysis in melanoma cells. Moreover, HIF-1α overexpression neutralized the promoting effects of UHRF1 silencing on proliferation, invasion, and glycolysis. In addition, UHRF1 silencing suppressed melanoma growth in mice.
conclusionUHRF1 silencing restrained the malignant phenotype of melanoma cells by inhibiting the HOXA9/HIF-1α axis-mediated glycolysis, thus suppressing tumor growth in mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.